Abstract
The early growth response-1 (Egr-1) gene encodes a Cys2-His2-type zinc-finger transcription factor. A broad range of extra cellular stimuli are known to lead to its induction thus furthering growth, proliferation, differentiation or apoptosis. Accordingly, Egr-1 is involved in a variety of diseases such as atherosclerosis or cancer. Among other functional elements, five serum response elements (SRE) have been identified in the promoter region of Egr-1. The Rho/Rho-kinase pathway has been shown to regulate actin reorganization via LIM-kinase mediated cofilin phosphorylation. Recent studies revealed the actin binding striated muscle activator of Rho signaling (STARS) to promote translocation of myosin related transcription factors (MRTFs) into the nucleus leading to serum response factor (SRF) activation. The ternary complex factor (TCF) Elk-1 eventually bridges the gap between SRF mediated gene transcription and the Raf/MEK/ERK pathway. Furthermore, the Egr-1 promoter has two cAMP response elements (CREs), whose relevance for gene expression is still controversial. An Egr-1 binding site (EBS) is located on the Egr-1 promoter itself arguing for a negative feedback mechanism. The acquired knowledge on transcriptional regulation, however, is not entirely understood. In this review we highlight upstream and downstream signaling in vitro and in vivo associated with Egr-1.
Keywords: Egr-1, signal transduction cascades, serum response factor, Rho-kinase, ERK1/2
Current Signal Transduction Therapy
Title: Concepts of Egr-1 Activation – A Hub for Signal Transduction Cascades
Volume: 5 Issue: 2
Author(s): Judith-Irina Pagel and Elisabeth Deindl
Affiliation:
Keywords: Egr-1, signal transduction cascades, serum response factor, Rho-kinase, ERK1/2
Abstract: The early growth response-1 (Egr-1) gene encodes a Cys2-His2-type zinc-finger transcription factor. A broad range of extra cellular stimuli are known to lead to its induction thus furthering growth, proliferation, differentiation or apoptosis. Accordingly, Egr-1 is involved in a variety of diseases such as atherosclerosis or cancer. Among other functional elements, five serum response elements (SRE) have been identified in the promoter region of Egr-1. The Rho/Rho-kinase pathway has been shown to regulate actin reorganization via LIM-kinase mediated cofilin phosphorylation. Recent studies revealed the actin binding striated muscle activator of Rho signaling (STARS) to promote translocation of myosin related transcription factors (MRTFs) into the nucleus leading to serum response factor (SRF) activation. The ternary complex factor (TCF) Elk-1 eventually bridges the gap between SRF mediated gene transcription and the Raf/MEK/ERK pathway. Furthermore, the Egr-1 promoter has two cAMP response elements (CREs), whose relevance for gene expression is still controversial. An Egr-1 binding site (EBS) is located on the Egr-1 promoter itself arguing for a negative feedback mechanism. The acquired knowledge on transcriptional regulation, however, is not entirely understood. In this review we highlight upstream and downstream signaling in vitro and in vivo associated with Egr-1.
Export Options
About this article
Cite this article as:
Pagel Judith-Irina and Deindl Elisabeth, Concepts of Egr-1 Activation – A Hub for Signal Transduction Cascades, Current Signal Transduction Therapy 2010; 5 (2) . https://dx.doi.org/10.2174/157436210791112190
DOI https://dx.doi.org/10.2174/157436210791112190 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preparation, Pharmacokinetic and Application of Gold Nanoclusters (AuNCs) in Tumor Treatment
Current Medicinal Chemistry Antibody-Drug Conjugate Targets
Current Cancer Drug Targets The Membrane-targeted Alkylphosphocholine Erufosine Interferes with Survival Signals from the Extracellular Matrix
Anti-Cancer Agents in Medicinal Chemistry Radioprotective Gene Therapy
Current Gene Therapy NAD+ Metabolism and NAD+-Dependent Enzymes: Promising Therapeutic Targets for Neurological Diseases
Current Drug Targets Novel Superactive Leptin Antagonists and their Potential Therapeutic Applications
Current Pharmaceutical Design Glia: An Important Target for Anti-Inflammatory and Antidepressant Activity
Current Drug Targets MATra - Magnet Assisted Transfection: Combining Nanotechnology and Magnetic Forces to Improve Intracellular Delivery of Nucleic Acids
Current Pharmaceutical Biotechnology Chlorotoxin-Conjugated Nanoparticles for Targeted Imaging and Therapy of Glioma
Current Topics in Medicinal Chemistry Tamoxifen as a Powerful Neuroprotectant in Experimental Stroke and Implications for Human Stroke Therapy
Recent Patents on CNS Drug Discovery (Discontinued) Modulation of Carbonic Anhydrase 9 (CA9) in Human Brain Cancer
Current Pharmaceutical Design Bioactive Triterpenic Acids: From Agroforestry Biomass Residues to Promising Therapeutic Tools
Mini-Reviews in Organic Chemistry P2Y Receptors: Focus on Structural, Pharmacological and Functional Aspects in the Brain
Current Medicinal Chemistry Ectodomain Shedding and Regulated Intracellular Proteolysis in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Lipid based Nanocapsules: A Multitude of Biomedical Applications
Current Pharmaceutical Biotechnology Modulation of MicroRNAs by <i>Euphorbia Microsciadia</i> Boiss in MDA-MB-231 Cell Line: New Possibilities in Breast Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Clinical Trials of Targeted Alpha Therapy for Cancer
Reviews on Recent Clinical Trials Role of Serum and Glucocorticoid-Inducible Kinase (SGK)-1 in Senescence: A Novel Molecular Target Against Age-Related Diseases
Current Medicinal Chemistry Vascular Endothelial Growth Factor: A New Paradigm for Targeting Various Diseases
Current Angiogenesis (Discontinued) Can γH2AX be Used to Personalise Cancer Treatment?
Current Molecular Medicine